SCHEDULE: Bank of America Reports 7.4% Stake in Q32 Bio

Bank of America Corp /DE/ has disclosed beneficial ownership of 2,205,390 shares, representing 7.4% of the outstanding common stock of Q32 Bio Inc.

Summary

• Bank of America Corp /DE/ has filed a Schedule 13G, indicating it beneficially owns 2,205,390 shares of Q32 Bio Inc. common stock.
• This ownership stake represents 7.4% of the company's outstanding common stock.
• The filing is made on behalf of Bank of America Corporation and its wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch Pierce Fenner & Smith, Inc.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than company performance or strategic shifts.

Positives

• Bank of America's significant stake may indicate confidence in Q32 Bio's long-term prospects.
• The filing clarifies the ownership structure, providing transparency for investors.

Negatives

• The filing does not provide any financial performance data or strategic updates for Q32 Bio.
• The nature of Bank of America's investment (e.g., proprietary trading, client assets) is not detailed.

Risks

• Potential for significant share sales by Bank of America could impact Q32 Bio's stock price.
• Changes in Bank of America's investment strategy could lead to divestment.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Q32 Bio Inc. It solely reports on the beneficial ownership of Bank of America Corp /DE/.

Management Comments

• "The beneficial ownership calculation relies on the 29,769,466 outstanding shares disclosed in the Form 10-Q by the issuer on August 5, 2026, which reports share totals as of August 3, 2026."
• "This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); and Merrill Lynch Pierce Fenner & Smith, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o)."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Bank of America's role as a major holder in the biotechnology sector, specifically within Q32 Bio.

Stakeholder Impact

• Shareholders: Increased institutional ownership can sometimes lead to greater stock liquidity and potentially attract further investment, but also introduces the risk of large block sales impacting price.
• Management of Q32 Bio: May need to engage with Bank of America regarding their investment strategy and outlook.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Bank of America Corp /DE/ for any changes in beneficial ownership.
• Observe Q32 Bio Inc.'s performance and strategic developments to assess the impact of institutional holdings.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Bank of America, Q32 Bio, Institutional Investor, Common Stock, Investment Holding